8158 Stock Overview
China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services.
China Regenerative Medicine International Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.12|
|52 Week High||HK$0.35|
|52 Week Low||HK$0.12|
|1 Month Change||-28.82%|
|3 Month Change||-34.60%|
|1 Year Change||-55.18%|
|3 Year Change||-13.57%|
|5 Year Change||-96.98%|
|Change since IPO||-91.36%|
Recent News & Updates
|8158||HK Biotechs||HK Market|
Return vs Industry: 8158 exceeded the Hong Kong Biotechs industry which returned -60.1% over the past year.
Return vs Market: 8158 underperformed the Hong Kong Market which returned -28% over the past year.
|8158 Average Weekly Movement||9.5%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||6.4%|
|10% most volatile stocks in HK Market||12.5%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 8158 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 8158's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015.
China Regenerative Medicine International Fundamentals Summary
|8158 fundamental statistics|
Is 8158 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|8158 income statement (TTM)|
|Cost of Revenue||HK$194.34m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.0091|
|Net Profit Margin||10.27%|
How did 8158 perform over the long term?See historical performance and comparison
Is 8158 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8158?
Other financial metrics that can be useful for relative valuation.
|What is 8158's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 8158's PE Ratio compare to its peers?
|8158 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
1061 Essex Bio-Technology
775 CK Life Sciences Int'l. (Holdings)
6826 Shanghai Haohai Biological Technology
8158 China Regenerative Medicine International
Price-To-Earnings vs Peers: 8158 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (20.7x).
Price to Earnings Ratio vs Industry
How does 8158's PE Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Earnings vs Industry: 8158 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the Asian Biotechs industry average (27.1x)
Price to Earnings Ratio vs Fair Ratio
What is 8158's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||13.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8158's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 8158 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8158's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8158's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is China Regenerative Medicine International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Regenerative Medicine International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine China Regenerative Medicine International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- China Regenerative Medicine International competitive advantages and company strategy can generally be found in its financial reports archived here.
How has China Regenerative Medicine International performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8158 has a high level of non-cash earnings.
Growing Profit Margin: 8158 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 8158 has become profitable over the past 5 years, growing earnings by 27.7% per year.
Accelerating Growth: 8158 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 8158 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (10.2%).
Return on Equity
High ROE: 8158's Return on Equity (23.5%) is considered high.
Discover strong past performing companies
How is China Regenerative Medicine International's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 8158's short term assets (HK$259.2M) exceed its short term liabilities (HK$157.8M).
Long Term Liabilities: 8158's short term assets (HK$259.2M) exceed its long term liabilities (HK$17.0M).
Debt to Equity History and Analysis
Debt Level: 8158's net debt to equity ratio (30.9%) is considered satisfactory.
Reducing Debt: 8158's debt to equity ratio has reduced from 39.5% to 33.6% over the past 5 years.
Debt Coverage: 8158's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 8158's interest payments on its debt are well covered by EBIT (101.4x coverage).
Discover healthy companies
What is China Regenerative Medicine International current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|China Regenerative Medicine International Dividend Yield vs Market|
|Company (China Regenerative Medicine International)||n/a|
|Market Bottom 25% (HK)||3.0%|
|Market Top 25% (HK)||8.8%|
|Industry Average (Biotechs)||1.0%|
|Analyst forecast in 3 Years (China Regenerative Medicine International)||n/a|
Notable Dividend: Unable to evaluate 8158's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8158's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8158's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8158's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 8158 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chuang Wang (42 yo)
Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...
CEO Compensation Analysis
|Chuang Wang's Compensation vs China Regenerative Medicine International Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||HK$1m||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||HK$1m||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||HK$245k||HK$245k|
Compensation vs Market: Chuang's total compensation ($USD152.87K) is below average for companies of similar size in the Hong Kong market ($USD241.94K).
Compensation vs Earnings: Chuang's compensation has been consistent with company performance over the past year.
Experienced Management: 8158's management team is considered experienced (4 years average tenure).
Experienced Board: 8158's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 8158 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|15 Sep 22||BuyHK$458,141||Chuang Wang||Individual||2,695,000||HK$0.17|
|07 Sep 22||BuyHK$510,969||Chuang Wang||Individual||3,080,000||HK$0.17|
|05 Sep 22||BuyHK$511,494||Chuang Wang||Individual||3,100,000||HK$0.16|
|26 Aug 22||BuyHK$493,847||Chuang Wang||Individual||2,975,000||HK$0.17|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
China Regenerative Medicine International Limited's employee growth, exchange listings and data sources
- Name: China Regenerative Medicine International Limited
- Ticker: 8158
- Exchange: SEHK
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$353.932m
- Shares outstanding: 2.85b
- Website: https://www.crmi.hk
Number of Employees
- China Regenerative Medicine International Limited
- Miramar Tower
- Suite 2310-2318
- Tsim Sha Tsui
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|8158||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Jul 2001|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.